Literature DB >> 2936441

Progestogens in the treatment of male sex offenders: a review.

A J Cooper.   

Abstract

The literature on the progestogens, medroxyprogesterone acetate (MPA) and cyproterone acetate (CPA), which are currently used in the treatment of deviant male hypersexuality, is reviewed. There are few adequately controlled trials, but clinical observations suggest that the drugs are reasonably effective in suppressing libido and sexual arousal in men. They are approximately equipotent and equivalent in this respect, but differ somewhat in their pharmacology. When used in conjunction with other measures, especially psychotherapy, they may benefit some sex offenders. The best results are likely in self-referred, nonrecidivist hypersexuals, with good social supports and who are motivated for treatment. The need for long-term placebo and comparison trials is stressed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936441     DOI: 10.1177/070674378603100116

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  4 in total

1.  Elderly Sexual Offenders.

Authors:  Brad D Booth
Journal:  Curr Psychiatry Rep       Date:  2016-04       Impact factor: 5.285

2.  Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys.

Authors:  Rajesh G Mishra; R Kent Hermsmeyer; Koichi Miyagawa; Philip Sarrel; Barry Uchida; Frank Z Stanczyk; Kenneth A Burry; D Roger Illingworth; Frank J Nordt
Journal:  J Clin Endocrinol Metab       Date:  2005-03-15       Impact factor: 5.958

3.  The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia.

Authors:  Stacy Anderson Light; Suzanne Holroyd
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

4.  Sexual absorption of vaginal progesterone: a randomized control trial.

Authors:  Kathryn S Merriam; Kristina A Leake; Mollie Elliot; Michelle L Matthews; Rebecca S Usadi; Bradley S Hurst
Journal:  Int J Endocrinol       Date:  2015-02-03       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.